Last reviewed · How we verify
NCT05679830
The Effects of CBD Isolate on Menstrual-Related Symptoms
Phase 2 trial testing Cannabidiol in Menstrual Discomfort in 33 participants. Completed in 23 September 2021.
23 September 2021
Quick facts
| Lead sponsor | Canopy Growth Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 23 September 2020 |
| Primary completion | 23 September 2021 |
| Estimated completion | 23 September 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cannabidiol (CANNABIDIOL) — full drug profile →
Conditions studied
- Menstrual Discomfort — all drugs for Menstrual Discomfort →
Sponsor
Canopy Growth Corporation — full company profile →
Who can join
Adults 18 to 55, female only, with Menstrual Discomfort. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this open-label clinical trial is to compared two different doses for treating menstrual-related symptoms in individuals who experience regular menstrual cycles (occurring for 4-8 days every 21-28 days). The main question it aims to answer is: (1) if there are changes in menstrual-related symptoms from baseline compared to all 3-months of cannabidiol (CBD) isolate consumption. Participants will complete a monthly baseline measure after they stop menstruating followed by taking CBD twice daily (BID) for five days for three menstrual cycles and complete the same measures. Researchers will compare 160mg of daily CBD isolate to 320mg of CBD isolate to see if there are differential effects on menstrual-related symptoms (MRS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05679830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cannabidiol
Trials testing the same drug.
- NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
- NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress · Phase 1, PHASE2 · recruiting
- NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
- NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
- NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Menstrual Discomfort
Currently open trials in the same condition.
- NCT06492148 — Myofascial Release Technique in Women With Primary Dysmenorrhea · NA · recruiting
Other Canopy Growth Corporation trials
Trials by the same sponsor.
- NCT05839964 — A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Qual · Phase 1, PHASE2 · completed
- NCT05317013 — CBD in Postmenopausal Women With Osteopenia · Phase 1 · terminated
- NCT05210634 — Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants · Phase 1 · completed
- NCT05026164 — Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity · Phase 2 · completed
- NCT04763252 — Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05679830 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Canopy Growth Corporation
- Last refreshed: 11 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing